Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Disposition of valproic acid in patients with liver disease.

Literature DB >> 346355

Disposition of valproic acid in patients with liver disease.

U Klotz, T Rapp, W A Müller.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：
Valerates
Valproic Acid

Year: 1978 PMID： 346355 DOI： 10.1007/bf00606683

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

× No keyword cloud information.

22 in total

1. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors: J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal: Clin Sci Date: 1961-08 Impact factor: 6.124

2. Classification of cirrhosis.

Authors: J T Galambos
Journal: Am J Gastroenterol Date: 1975-12 Impact factor: 10.864

3. Influence of acute viral hepatitis on phenytoin kinetics and protein binding.

Authors: T F Blaschke; P J Meffin; K L Melmon; M Rowland
Journal: Clin Pharmacol Ther Date: 1975-06 Impact factor: 6.875

Review 4. Drug disposition and liver disease.

Authors: G R Wilkinson; S Schenker
Journal: Drug Metab Rev Date: 1975 Impact factor: 4.518

5. [Problems in serum-level determination during valproic acid therapy].

Authors: H Schäfer; H Reith; R Jacobs; K H Gabriel
Journal: Arzneimittelforschung Date: 1977

6. Blood levels of drug at the equilibrium state after multiple dosing.

Authors: J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal: Nature Date: 1965-09-18 Impact factor: 49.962

7. Pharmacokinetic studies with valproic acid in man.

Authors: U Klotz
Journal: Arzneimittelforschung Date: 1977

8. [Pharmacokinetics of glymidine (glycodiazine) and tolbutamide in acute and chronic liver diseases].

Authors: H Held; R Eisert; H F von Oldershausen
Journal: Arzneimittelforschung Date: 1973-12

9. Pharmacokinetics of di-n-propylacetate in epileptic patients.

Authors: F Schobben; E van der Kleijn; F J Gabreëls
Journal: Eur J Clin Pharmacol Date: 1975-02-28 Impact factor: 2.953

Review 10. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

Authors: R M Pinder; R N Brogden; T M Speight; G S Avery
Journal: Drugs Date: 1977-02 Impact factor: 9.546

15 in total

Review 1. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors: R Zini; P Riant; J Barré; J P Tillement
Journal: Clin Pharmacokinet Date: 1990-09 Impact factor: 6.447

Review 2. Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors: Gail D Anderson; Shahin Hakimian
Journal: Clin Pharmacokinet Date: 2014-01 Impact factor: 6.447

Review 3. Guide to drug dosage in hepatic disease.

Authors: N M Bass; R L Williams
Journal: Clin Pharmacokinet Date: 1988-12 Impact factor: 6.447

4. Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.

Authors: R L Semmes; D D Shen
Journal: Pharm Res Date: 1990-05 Impact factor: 4.200

Review 5. Clinical pharmacokinetics of valproic acid.

Authors: R Gugler; G E von Unruh
Journal: Clin Pharmacokinet Date: 1980 Jan-Feb Impact factor: 6.447

6. Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.

Authors: E Perucca
Journal: Clin Pharmacokinet Date: 1984-01 Impact factor: 6.447

Review 7. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors: Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal: Drug Saf Date: 2009 Impact factor: 5.606